Syntex Laboratories
Syntex Laboratories is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Syntex Laboratories.
Syntex Laboratories is a company.
Key people at Syntex Laboratories.
Syntex Laboratories, originally Syntex S.A., was a pioneering pharmaceutical company founded in Mexico City in 1944, specializing in steroid hormones derived from Mexican yams (barbasco plants).[1][2][5][6] It revolutionized medicine by developing low-cost synthesis of progesterone, cortisone, and the first orally active progestins like norethindrone, leading to early oral contraceptives such as Norinyl (1964) and anti-inflammatories like Naprosyn (1975).[1][2][3][6] The company expanded into diagnostics (Syva), veterinary drugs, agribusiness, dental products, and beauty care, achieving rapid growth before its acquisition by Roche in 1994.[1][2][4]
Syntex served global healthcare markets, addressing chronic conditions like arthritis, heart disease, allergies, and reproductive health, while solving high-cost steroid production through innovative chemistry from plant sources.[2][3][5] Its growth momentum peaked in the 1960s-1970s with U.S. entry (1947), Panama incorporation (1957), Palo Alto headquarters (1964), and acquisitions, though it faced FDA challenges in the 1970s.[1][4]
Syntex trace its roots to 1944 when American chemist Russell Marker, frustrated with U.S. industry, partnered with Hungarian Emeric Somlo and German Federico Lehmann of Laboratorios Hormona to form Syntex S.A. in Mexico City.[1][2][3][5][6] Marker had developed a breakthrough process to synthesize progesterone from inexpensive Mexican yams, producing kilos at scale after leaving his prior role.[2][5] Disagreements over compensation led Marker to depart shortly after, taking his notebooks, but the company quickly recruited George Rosenkranz and, in 1949, Carl Djerassi—later dubbed the "father of the pill"—who drove steroid innovations.[3][6]
Early traction came from selling progesterone at $50/gram by 1945, fueling cortisone synthesis in 1951 and the first oral contraceptive progestin (norethindrone) that year.[1][3][5][6] Pivotal moments included U.S. market entry via Chemical Specialties (1947), public listing in Panama (1957), and relocation to Palo Alto (1964), marking its evolution from bulk chemicals to branded pharmaceuticals.[1][2]
Syntex rode the mid-20th-century steroid hormone revolution, capitalizing on post-WWII demand for affordable cortisone (for arthritis) and progesterone derivatives amid booming reproductive health needs.[3][5] Timing was ideal: Marker’s yam-based process democratized steroids when natural extraction was scarce and expensive, influencing global pharma like Glaxo’s licensing of hecogenin routes for blockbusters (e.g., Betnovate).[3] Market forces favored it—Mexico’s lax regulations, yam abundance, and U.S. FDA bans on alternatives like DES boosted veterinary lines.[4][5]
It shaped the ecosystem by kickstarting Mexico’s steroid industry, inspiring competitors, and advancing oral contraceptives, which transformed women’s health and family planning worldwide.[2][3][6] Syntex’s alumni, like ALZA founder Alex Zaffaroni, spawned spin-offs, while its diagnostics and agribusiness arms diversified pharma beyond pills.[1][7]
Though defunct since Roche’s 1994 acquisition, Syntex’s legacy endures in modern endocrinology, generics, and hormone therapies derived from its breakthroughs.[2] Post-acquisition, its innovations integrated into Roche’s portfolio, influencing ongoing steroid drug development. Trends like biotech revival of plant-based synthesis and precision reproductive medicine could echo Syntex’s model, potentially inspiring new ventures in sustainable pharma. Its story—from yam fields to the pill—remains a blueprint for chemistry-driven disruption in healthcare.[3][5]
Key people at Syntex Laboratories.